Showing results (251-260 of 266) with videos related to
Sort By:
Pageof 27
BMC Cancer|May 11, 2021
No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in GermanyRoman Rüdiger, Franziska Geiser, Manuel Ritter, et al.Journal of Clinical Medicine|July 13, 2024
Study Protocol of a Randomized, Two-Arm, Phase I/II Trial Investigating the Feasibility, Safety, and Efficacy of Local Treatment with US-Guided High-Intensity Focused Ultrasound in Combination with Palliative Chemotherapy in Inoperable Pancreatic CancerMilka Marinova, David-Alexis Khouri, Jim Küppers, et al.Blood|January 14, 2025
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialMarc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, et al.Frontiers in Oncology|April 7, 2023
Postoperative adjuvant radiochemotherapy with cisplatin versus adjuvant radiochemotherapy with cisplatin and pembrolizumab in locally advanced head and neck squamous cell carcinoma- the study protocol of the Adrisk trialSusanne Wiegand, Gunnar Wichmann, Jeannette Vogt, et al.Leukemia|July 23, 2020
Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsEHartmut Goldschmidt, Marc-Andrea Baertsch, Jana Schlenzka, et al.Journal of Cancer Research and Clinical Oncology|October 14, 2022
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.Leukemia|February 9, 2020
Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trialHartmut Goldschmidt, Elias K Mai, Jan Dürig, et al.Cancers|October 13, 2021
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 TrialEva-Maria Klein, Diana Tichy, Hans J Salwender, et al.Blood Cancer Journal|January 8, 2021
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myelomaMarc-Andrea Baertsch, Elias K Mai, Thomas Hielscher, et al.Infection|November 28, 2023
Early combination therapy of COVID-19 in high-risk patientsHans Martin Orth, Charlotte Flasshove, Moritz Berger, et al.Pageof 27